Executing “Vision 110 – Stage 1 –” and FY2025 Targets
First written in FY2023. 5 of 12 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2026Revenue growth target achieved, margin target not achievedAnnual report
「Against the quantitative targets under the medium-term management plan Vision 110－Stage1－ of average annual consolidated revenue growth of at least 2% and operating profit before R&D expenses as a percentage of revenue of at least 16%, our group achieved average annual consolidated revenue growth of 3.7% and operating profit before R&D expenses as a percentage of revenue of 12.4%.」
The Stage1 target for average annual revenue growth was achieved at 3.7%, while operating profit before R&D expenses as a percentage of revenue was 12.4%, below the target of at least 16%. - FY2026-H1RestatedAnnual report
「For the fiscal year ending March 2026, the final year of Stage1, the company adopted “Establishing a business structure for realizing Vision 110” as its management policy and is working to achieve its goals.」
Vision 110 Stage1 has entered its final year, and the Company is continuing operations toward achieving the plan's targets. - FY2025Revenue growth target achieved, profit margin target expected to be missedAnnual report
「Consolidated revenue for the consolidated fiscal year increased 8.8% year on year, and operating profit before R&D expenses as a percentage of revenue was 17.7%. For Vision 110－Stage1－ as a whole, the Company forecasts average annual revenue growth of 3.9% and operating profit before R&D expenses as a percentage of revenue of 13.0%.」
While the full-year forecast for average annual revenue growth was 3.9%, above the Stage1 target of at least 2%, operating profit before R&D expenses as a percentage of revenue is forecast at 13.0%, below the target of at least 16%. The Company stated that the profit margin target is expected to be missed. - FY2025-H1RestatedAnnual report
「In the fiscal year ending March 2025, the second year of the plan, the company adopted “Achieving transformation” as its management policy and is actively pursuing ① achieving transformation in drug discovery, ② expanding its pipeline, ③ maximizing the uptake of new drugs, and ④ improving cost competitiveness, among other initiatives.」
As the second year of Vision 110－Stage1－, the Company is continuing the planned business activities. - FY2024WorsenedAnnual report
「Consolidated revenue for the consolidated fiscal year increased 5.5% year on year, while operating profit before R&D expenses as a percentage of revenue was 11.7%.」
Against Stage1 targets of average annual revenue growth of at least 2% and operating profit before R&D expenses as a percentage of revenue of at least 16%, the Company reported operating profit before R&D expenses as a percentage of revenue of 11.7% for the fiscal year. - FY2024-Q3RestatedAnnual report
「In the fiscal year marking the Group’s 100th anniversary, we launched the newly formulated long-term vision, “Vision 110 (FY2023–FY2032),” and medium-term management plan, “Vision 110—Stage 1—(FY2023–FY2025).”」
Vision 110－Stage1－ continues as the medium-term plan for fiscal years 2023 to 2025. - FY2024-Q2RestatedAnnual report
「In the fiscal year marking the Group’s 100th anniversary, we launched the newly formulated long-term vision, “Vision 110 (FY2023–FY2032),” and medium-term management plan, “Vision 110—Stage 1—(FY2023–FY2025).”」
Vision 110－Stage1－ continues as the medium-term plan for fiscal years 2023 to 2025. - FY2024-Q1RestatedAnnual report
「In the fiscal year marking the Group’s 100th anniversary, we launched the newly formulated long-term vision, “Vision 110 (FY2023–FY2032),” and medium-term management plan, “Vision 110—Stage 1—(FY2023–FY2025).”」
The Company reaffirmed that it had begun first-year operations under Vision 110－Stage1－, the medium-term management plan for fiscal years 2023 to 2025. - FY2023First statedAnnual report
「Under the medium-term management plan, “Vision 110 – Stage 1 –,” we adopted the statement “Transforming the business structure toward realizing Vision 110” and are pursuing the following 5 business strategies, with the aim of achieving our performance targets and enhancing stakeholder support and recognition. Performance targets for FY2025: (a) numerical targets on a consolidated basis: growth—revenue CAGR of at least 2%; profitability—operating profit before R&D expenses (operating profit plus R&D expenses) as a percentage of revenue of at least 16%.」
Stage 1, covering FY2023 through FY2025, set targets of at least 2% revenue CAGR and operating profit before R&D expenses of at least 16% of revenue for FY2025.